Skip to Main Content
Skip Nav Destination

Experts Call for Data, Deep Breath, on CARs

January 9, 2024

Abstract: Despite an FDA alert in late November about a possible link between chimeric antigen receptor (CAR) T-cell therapy and the development of secondary hematologic malignancies, as well as the first published report of a patient case and a change in the boxed warning on one CAR product in December, experts in cellular and gene therapies and immunology suggest no changes in clinical practice in a commentary.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal